Clinical trial
Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel…
NCT00133250 · Deutsches Herzzentrum Muenchen, Other · Completed
Key facts
| NCT number | NCT00133250 |
|---|---|
| Title | Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3) |
| Official title | Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3) |
| Lead sponsor | Deutsches Herzzentrum Muenchen, Other |
| Collaborators | Technical University of Munich |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Myocardial Infarction |
| Intervention type | Drug, Other |
| Interventions | Abciximab, Placebo Heparin Sodium |
| Enrollment | 800 |
| Start date | Jun 1, 2003 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Aug 23, 2005 |
| Last update posted | Mar 16, 2010 |
| Countries | Austria, Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: